Alkem Laboratories Limited - Asset Resilience Ratio
Alkem Laboratories Limited (ALKEM) has an Asset Resilience Ratio of 31.91% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ALKEM capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Alkem Laboratories Limited's Asset Resilience Ratio has changed over time. See Alkem Laboratories Limited (ALKEM) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Alkem Laboratories Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Alkem Laboratories Limited (ALKEM) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs15.48 Billion | 7.63% |
| Short-term Investments | Rs49.26 Billion | 24.28% |
| Total Liquid Assets | Rs64.74 Billion | 31.91% |
Asset Resilience Insights
- Very High Liquidity: Alkem Laboratories Limited maintains exceptional liquid asset reserves at 31.91% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Alkem Laboratories Limited Industry Peers by Asset Resilience Ratio
Compare Alkem Laboratories Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Alkem Laboratories Limited (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Alkem Laboratories Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 24.32% | Rs43.03 Billion ≈ $465.35 Million |
Rs176.91 Billion ≈ $1.91 Billion |
-0.17pp |
| 2024-03-31 | 24.49% | Rs38.15 Billion ≈ $412.54 Million |
Rs155.75 Billion ≈ $1.68 Billion |
+4.62pp |
| 2023-03-31 | 19.88% | Rs27.34 Billion ≈ $295.71 Million |
Rs137.57 Billion ≈ $1.49 Billion |
+2.19pp |
| 2022-03-31 | 17.69% | Rs24.89 Billion ≈ $269.13 Million |
Rs140.69 Billion ≈ $1.52 Billion |
+3.89pp |
| 2021-03-31 | 13.79% | Rs15.89 Billion ≈ $171.85 Million |
Rs115.19 Billion ≈ $1.25 Billion |
+12.41pp |
| 2020-03-31 | 1.38% | Rs1.38 Billion ≈ $14.88 Million |
Rs99.46 Billion ≈ $1.08 Billion |
-2.62pp |
| 2019-03-31 | 4.01% | Rs3.29 Billion ≈ $35.58 Million |
Rs82.08 Billion ≈ $887.68 Million |
+1.66pp |
| 2018-03-31 | 2.34% | Rs1.80 Billion ≈ $19.44 Million |
Rs76.66 Billion ≈ $829.01 Million |
-6.61pp |
| 2017-03-31 | 8.95% | Rs5.88 Billion ≈ $63.59 Million |
Rs65.68 Billion ≈ $710.31 Million |
+3.10pp |
| 2016-03-31 | 5.85% | Rs3.24 Billion ≈ $35.02 Million |
Rs55.35 Billion ≈ $598.55 Million |
-7.98pp |
| 2015-03-31 | 13.83% | Rs7.33 Billion ≈ $79.23 Million |
Rs52.96 Billion ≈ $572.72 Million |
+7.38pp |
| 2014-03-31 | 6.46% | Rs2.81 Billion ≈ $30.36 Million |
Rs43.48 Billion ≈ $470.19 Million |
+4.79pp |
| 2013-03-31 | 1.66% | Rs673.10 Million ≈ $7.28 Million |
Rs40.48 Billion ≈ $437.80 Million |
-41.47pp |
| 2012-03-31 | 43.13% | Rs13.73 Billion ≈ $148.45 Million |
Rs31.82 Billion ≈ $344.16 Million |
+7.85pp |
| 2011-03-31 | 35.28% | Rs9.14 Billion ≈ $98.80 Million |
Rs25.89 Billion ≈ $280.03 Million |
-- |
About Alkem Laboratories Limited
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective… Read more